Intellia presents positive data for hereditary angioedema treatment
LONDON - EKF Diagnostics Holdings plc (AIM:EKF), a global diagnostics business, purchased 414,793 of its ordinary shares on Monday at a weighted average price of 26.18 pence per share, according to a company statement released Tuesday.
The shares, acquired on October 27, will be held in treasury. The purchase included transactions at prices ranging from 26.00 pence to 26.20 pence per share across three separate trades executed on the AIM exchange.
Following the buyback, EKF’s total issued share capital consists of 449,093,790 ordinary shares, with 5,264,908 shares held in treasury. The total number of ordinary shares carrying voting rights is now 443,828,882.
As part of the transaction, EKF acquired 124,000 ordinary shares from Harwood, which acted as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. The company purchased 41,333 shares from Oryx and 82,667 shares from NASCIT at 26.20 pence per share.
The company noted that Harwood facilitated this transaction to ensure that the aggregate indirect beneficial interest of Christopher Mills, a Non-Executive Director, remains at approximately the same level and does not exceed 30% of the total voting rights following any repurchases. After the transaction, Mills’ aggregate indirect interest in the company stands at 130,877,000 ordinary shares.
EKF Diagnostics operates five manufacturing sites across the US and Germany, selling into over 120 countries worldwide. The company specializes in point-of-care analyzers in hematology and diabetes, as well as life sciences services providing enzymes and custom products for diagnostic, food, and industrial applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.